News and Trends 26 Oct 2022
Partnership between Paradigm4 and Alnylam accelerates drug target discovery
…obesity and metabolic syndrome – a condition impacting more than 20% of adults worldwide. Cardiometabolic disease These findings support the potential of INHBE as a novel therapeutic target to be…